Type 2 diabetes mellitus (T2DM) is a recognized risk factor for cardiovascular (CV) disease (CVD). In a large, prospective, cohort study of individuals ≥30 years of age, 18% of patients with diabetes developed incident CVD over 5.5 years of follow-up. Diabetes in itself increases mortality risk, but the mortality rate nearly doubles in combination with manifestations of CVD [e.g. myocardial infarction (MI) or stroke], translating into an estimated reduction in life expectancy of 12-years. Despite this alarming risk, 30–50% of patients with diabetes do not meet guideline-recommended treatment goals for managing CV risk. Only 14% of NHANES (National Health and Nutrition Examination Survey) and BRFSS (Behavioral Risk Factor Surveillance System Survey) participants with diabetes achieved HbA1c, blood pressure, LDL-cholesterol, and non-smoking goals. Accordingly, providing optimal cardioprotective treatment strategies remains a major unmet need in this population. Addressing this treatment gap is imperative because of the burdensome prevalence of T2DM, which impacts an estimated 58 million people in Europe, 46 million in the United States, and it is expected to reach 629 million globally by 2045.
Roundtable, European Heart Journal, , ehy677.